Arrowhead Pharmaceuticals, Inc. announced that the European Commission (EC) has formally granted marketing authorization for Redemplo (plozasiran), a small interfering RNA (siRNA) medicine, as an adjunct to diet… read more.
The Ministry of Health, Labour and Welfare in Japan has granted approval for Sarclisa (isatuximab) subcutaneous (SC) formulation in combination with approved standard-of-care regimens for the treatment of… read more.
Genital herpes is a lifelong infection. While available treatments can manage symptoms, they cannot cure the infection or prevent transmission. Now, Yale School of Medicine researchers have taken… read more.
Incyte Biosciences Japan G.K. announced that Japan’s MHLW has approved Minjuvi (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell… read more.
Scientists at Queen Mary University of London and Barts Health NHS Trust have invented an AI algorithm which could transform how heart failure is screened and diagnosed. Known… read more.
Two deadly infectious diseases, Ebola https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260834 and hantavirus https://www.cmaj.ca/lookup/doi/10.1503/cmaj.260789, have made headlines in recent weeks as they pose serious threats to public health. They both require rigorous infection and prevention control… read more.
Merck, known as MSD outside of the United States and Canada, announced that the FDA has approved an expanded indication for Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to include… read more.
HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces results from the pivotal Phase II registration study of fanregratinib (HMPL-453) in patients with intrahepatic cholangiocarcinoma (“ICC”) will be presented… read more.
Nurix Therapeutics announced updated clinical data from the Company’s ongoing NX-5948-301 Phase 1a/b clinical trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic… read more.
Using a massage gun on or around the eyes risks major tearing and bruising to the retina—the light sensitive tissue at the back of the eye—doctors warn in… read more.
Long-term survival modeling of Boehringer Ingelheim’s oral preferential PDE4B inhibitor, nerandomilast, predicts the therapy could extend survival by up to 5.4 years in adults with idiopathic pulmonary fibrosis… read more.
Pfizer Inc. announced that the FDA has approved an expanded indication for Hympavzi (marstacimab-hncq) to include the treatment of patients with hemophilia A or B 12 years and… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
